Process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate

Information

  • Patent Grant
  • 7557238
  • Patent Number
    7,557,238
  • Date Filed
    Thursday, September 18, 2003
    21 years ago
  • Date Issued
    Tuesday, July 7, 2009
    15 years ago
Abstract
In one aspect, the present invention provides a novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate, a key intermediate for the preparation of HMG-CoA reductase inhibitor.
Description
PRIORITY CLAIM

The present application claims the benefit under 35 U.S.C. § 371 of International Application No.: PCT/IN03/00317, filed Sep. 18, 2003, the entire contents of which is hereby incorporated herein by reference.


FIELD OF THE INVENTION

The present invention relates to a novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate, a key intermediate for the preparation of a HMG CoA reductase inhibitor.


BACKGROUND OF THE INVENTION

HMG CoA reductase inhibitors are pharmaceutically active compounds used for inhibition of cholesterol biosynthesis. A group of compounds called ‘statins’ comprising lovastatin, simvastatin, mevastatin, pravastatin, atorvastatin, rosuvastatin, cerivastatin and fluvastatin show antilipidemic activity and are widely known HMG CoA reductase inhibitors.


The ester derivative of the compound of Formula I




embedded image



is a valuable chiral synthon for synthesizing atorvastatin.


SUMMARY OF THE INVENTION

In one aspect, the present invention provides a novel process for the preparation of the compound of Formula I. In another aspect, the process employs novel intermediates.


The present invention relates to a novel process for preparing a compound of Formula I




embedded image



comprising

  • hydrolysis of a compound of Formula II




embedded image


  • wherein, the compound of Formula II is obtained from a compound of Formula III





embedded image


  • wherein Alk is a straight or branched C1-C6 alkyl; and

  • wherein the compound of Formula III is obtained from a compound of Formula IV





embedded image


  • wherein Alk is a straight or branched C1-C6 alkyl.



The process of the present invention has several advantages over the prior art including: higher yield during conversion of the compound of Formula III to the compound of Formula II as the hydroxy group is protected, reactions after protection with TBDPS can be followed by TLC, low consumption of reagents as the hydroxy group is protected, and reduced levels of undesired side products.







DETAILED DESCRIPTION OF CERTAIN PREFERRED EMBODIMENTS OF THE INVENTION

In one aspect, the present invention provides a novel process for the preparation of a compound of Formula I




embedded image



comprising

  • removal of the TBDPS group from a compound of Formula II




embedded image


  • wherein the compound of Formula II is obtained from a compound of Formula III





embedded image


  • wherein Alk is a straight or branched C1-C6 alkyl; and

  • wherein the compound of Formula III is obtained from a compound of Formula IV





embedded image


  • wherein Alk is a straight or branched C1-C6 alkyl.



An exemplary process according to the present invention is depicted in Scheme I below:




embedded image



wherein Alk is a straight or branched C1-C6 alkyl.


In one embodiment, the inventive process employs a hydroxy protecting group and utilizes novel intermediates of Formulae II and III. For example, TBDPS (tert-butyl diphenyl silyl) may be employed.


In certain exemplary embodiments, a compound of Formula I may be obtained by removal of the TBDPS group from a compound of Formula II by conventional methods.


In certain other embodiments, a compound of Formula II may be obtained by treating a compound of Formula III with a carbanion, which is generated by the reaction of tert-butyl acetate with lithium diisopropylamide.


In yet other embodiments, a compound of Formula III may be obtained by reacting a compound of Formula IV with tert-butyl diphenyl silyl chloride.


The illustrated embodiments have been set forth only for the purposes of example and should not be taken as limiting the invention. Therefore, it should be understood that, within the scope of the appended claims, the invention may be practiced other than specifically described herein.


Example 1
Ethyl 4-cyano-3-(tert-butyldiphenylsilyloxy)-butanoate

Imidazole (6.5 g, 0.095 mol) was added to a chilled solution (−5 to −10° C.) of ethyl 4-cyano-3-hydroxybutanoate (10 g, 0.063 mol) in dichloromethane (100 ml) under stirring, followed by tert-butyl diphenyl silyl chloride (15.7 g, 0.057 mol). After stirring for 4 hours at room temperature, water (250 ml) was added to the reaction mixture and layers separated. The aqueous layer was extracted with dichloromethane (100 ml) and combined with the organic layer. The combined organic layer was evaporated to give title compound.


Yield: 22 g.


Example 2
tert-Butyl 6-cyano-5-(tert-butyldiphenylsilyloxy)-3-oxohexanoate

A solution of n-butyl lithium in hexane (14.4 ml, 0.21 mol) was added to a chilled solution (−5 to −10° C.) of diisopropylamlie (23.2 g, 0.23 mol) in THF (100 ml) and the resulting mixture was stirred at −5 to −10° C. for 30 minutes. After chilling the reaction to about −45° C., tert-butyl acetate (26 g, 0.21 mol) was added and the resulting reaction mixture was stirred at −20-30° C. for 1 hour. A solution of ethyl 4-cyano-3-(tert-butyldiphenylsilyloxy)-butanoate (20 g, 0.050 mol) in THF (20 ml) was added to the reaction mixture at about −75° C. and further stirred −70-−75° C. for 2 hours. Methanol (15 ml) was added to the reaction mixture followed by water (200 ml) and layers were separated. The organic layer was preserved. The aqueous layer was extracted with ethyl acetate (2×200 ml) and combined with the organic layer. The combined organic layer was evaporated to give the title compound.


Yield: 20 g.

Claims
  • 1. A process for the preparation of a compound of Formula I:
  • 2. A compound of Formula II:
  • 3. A compound of Formula III:
PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/IN03/00317 9/18/2003 WO 00 9/27/2004
Publishing Document Publishing Date Country Kind
WO2005/026107 3/24/2005 WO A
US Referenced Citations (7)
Number Name Date Kind
5155251 Butler et al. Oct 1992 A
5216174 Butler et al. Jun 1993 A
6274740 Lin et al. Aug 2001 B1
6528661 Niddam et al. Mar 2003 B2
20020099224 Niddam et al. Jul 2002 A1
20030114685 Niddam-Hildesheim et al. Jun 2003 A1
20030175338 Singh et al. Sep 2003 A1
Foreign Referenced Citations (6)
Number Date Country
WO 9703960 Feb 1997 WO
WO 0243667 Jun 2002 WO
WO 03004450 Jan 2003 WO
WO 03004455 Jan 2003 WO
WO 03004456 Jan 2003 WO
WO 03016317 Feb 2003 WO
Related Publications (1)
Number Date Country
20050065362 A1 Mar 2005 US